Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis

NCT00577850 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00577850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00577850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis
Lead sponsor
Warner Chilcott
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2002
Completion date
February 29, 2004
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

osteopenia, osteoporosis